BAB V SIMPULAN DAN SARAN
5.2 Saran
Perbaikan pada pengisian kelengkapan rekam medis yang meliputi nilai CAS dan derajat NOSPECS saat pasien datang dan kontrol sehingga dapat membantu dalam meningkatkan keberhasilan tatalaksana pasien TAO.
45
DAFTAR PUSTAKA
1. American Academy of Ophthalmology. Orbit, Eyelids, and Lacrimal System.
Section 7. San Fransisco: AAO; 2020-2021. Hal 5-20 dan 53-61
2. Kanski JJ, Brod B. Clinical Ophthalmology. Edition 7. Philadelphia : Elsevier Saunders; 2011. Hal 84-89
3. Sahlı E, Kaan G. Thyroid-associated Ophthalmopathy. Turk J Ophthalmol 2017;47:94-105
4. Subekti I. Oftalmopati Graves: Perbandingan Karakterisitik Klinis, Kadar Hormon, dan Kadar Antibodi Reseptor TSH. eJournal Kedokteran Indonesia. 2018; 6(1), 33- 38
5. Novaes P, Ana BD, Terry JS. Update on thyroid-associated Ophthalmopathy with a special emphasis on the ocular surface. Clinical Diabetes and Endocrinology 2016; 2:19
6. Villani E, Francesco V, Roberto S et al. Corneal Involvement in Graves’
Orbitopathy: An In Vivo Confocal Study. IOVS, September 2010, Vol. 51, No. 9 7. Tortora F, Mario C, marco T el al. Disease Activity in Graves’
Ophthalmopathy:Diagnosis with Orbital MR Imaging and Correlation with Clinical Score. The Neuroradiology Journal 26: 555-564, 2013
8. Mathur C, Singh S, Sharma S. Prevalence and risk factors of thyroid‑associated ophthalmopathy among Indians. Int J Adv Med 2016;3:662‑5.
9. Kvetny J, Puhakka KB, Rohl L. Magnetic resonance imaging determination of extraocular eye muscle volume in patients with thyroid-associate ophthalmopathy and proptosis. Acta Ophthalmol Scand. 2006;84: 419-423
10. Kim JW, Young JW, Jin SY. Is modified clinical activity score an accurate indicator of diplopia progression in Graves’ orbitopathy patients?. Endocrine Journal.2016, 63 (12), 1133-1140
11. Nagy EV, Toth J, Kaldi I et al. Graves ophthalmopathy: eye muscle involvement in patients with diplopia. Eur J Endocrinol. 200;142: 591-597
12. Wang Y, Amy P,Raymond SD. Thyroid Eye Disease: How A Novel Therapy May Change The Treatment Paradigm. Therapeutics and Clinical Risk Management 2019:15 1305–1318
13. American Academy of Ophthalmology. Fundamentals and Principles of Ophthalmology. Section 2. San Fransisco: AAO; 2020-2021. Hal 5-42
14. Vaughan D, Asbury T, Riordan P et al. General Ophthalmology. Edisi 19. London.
Lange. 2016. Hal 17-20
15. Standring S, Borley NR, et al., eds. Gray's anatomy : the anatomical basis of clinical practice (40th ed.). London: Churchill Livingstone. 2008. ISBN. 2008;
978-0-8089-2371-8
16. Ort V, Bogart BI. Elsevier's integrated anatomy and embryology. Philadelphia, Pa.:
Elsevier Saunders. ISBN.2007; 978-1-4160-3165-9
17. The Thyroid Gland Anatomy and Physiology II. the Regents of University of Michigan Medical School.2012
46
18. Hall JE, Guyton AC. Guyton and Hall textbook of medical physiology (12th ed.).
Philadelphia, Pa.: Saunders/Elsevier. ISBN. 2011; 978-1-4160-4574-8
19. Walter F, Boron. Medical Physiology: A Cellular And Molecular Approach, Elsevier/Saunders, ISBN. 2003: 1-4160-2328-3.
20. The Indonesian Society of Endocrinology Task Force on Thyroid Diseases.
Indonesian Clinical Practice Guidelines for Hipertiroidisme.ISSN.2012.Vol. 27 No.0857-1074
21. Subekti I, Ranakusuma AB, Moeloek NDF et al. Association of TSH receptor antibody, thyroid stimulating antibody, and thyroid blocking antibody with clinical activity score and degree of severity of Graves’ ophthalmopathy.
Acta Medica Indonesiana. 2012;44(2):114-21
22. Ginsberg J. Diagnosis and management of Graves’ disease. CMAJ. 2003;168:575- 585
23. Noor WH, Saraswati MR. Terapi penyakit graves dengan sodium iodida-131.
Denpasar: E-jurnal Medika Udayana; 2013
24. Weetman AP. Graves disease dalam: Medical Progress. The New England Jof Medicine.2011;343(17):1236-48
25. Wiersinga WM, Smit T, van der Gaag R et al. Temporal relationship between onset of Graves’ophthalmopathy and onset of thyroidal Graves’disease. Journal of Endocrinological Investigation 1988; 11: 615–619.
26. Khalilzadeh O, Noshad S, Rashidi A et al. Graves' ophthalmopathy: a review of immunogenetics. Curr Genomics. 2011;12(8):564-575
27. Bagheri N, Brynn NW, Charles MC et al. The Wills Eye Manual Edisi 7.
Philadelphia : Wolters Kluwer 2017 Hal 277-282
28. Aktaran S, Akarsu E, Erbagci I et al. Comparison of intravenous methylprednisolone therapy vs. oral methylprednisolone therapy in patients withmGraves’ ophthalmopathy. Int J Clin Pract, January 2007; 61, 1, 45–51 29. Levine MR. Manual of Oculoplastic Surgery. Edition 4. Ohio : Slack incorporate;
2010. Hal 20-49
30. Bario BJ, Sabater AL, Bonet-Farriol E et al. Grave’s ophthalmopathy: VISA versus EUGOGO classification, assesment, and management. Hindawi Journal of Ophthalmology.2015:1-16
31. Roy A, Deep D, Sujoy G et al. Efficacy and safety of low dose oral prednisolone as compared to pulse intravenous methylprednisolone in managing moderate severe Graves’ orbitopathy: A randomized controlled trial. Indian J Endocrinol Metab. 2015 May-Jun; 19(3): 351–358
32. Dagi LR, Zoumalan CI, Konrad H et al. Correlation between extraocular muscle size and motility restriction in thyroid eye disease. Ophthal Plast Reconstr Surg. 2011; 27: 102-110
33. Mourits MP, Koornneef L, Wiersinga WM et al. Clinical criteria for the assessment of disease activity in Graves’ ophthalmopathy: a novel approach. Br J Ophthalmol.
1989; 73(8):639–644
34. Li Q, Huijing Y, Yungang D et al. Clinical characteristics of moderate-to-severe thyroid associated ophthalmopathy in 354 Chinese cases. 2017. PLoS ONE 12(5):
e0176064
35. Bartalena L, Lelio B, Kostas B et al. The 2016 European Thyroid Association/European Group on Graves’ Orbitopathy Guidelines for the Management of Graves’ Orbitopathy. Eur Thyroid J 2016;5:9–26
36. Lavaju P, Badhu BP, Maskey R. Pattern of ocular manifestations in patients with thyroid disease presenting in Eastern Nepal.Thyroid Res Pract 2019;16:20-5.
37. Prigione SO. The influence of sex and gender on the immune response.
Autoimmunity ReviewsmVolume 11, Issues 6–7, May 2012, Pages A479-A485 38. Liu X, Shu w, Li Q et al. Short and long‑term effects of high‑dose intravenous
methylprednisolone pulse therapy on thyroid‑associated ophthalmopath. Exp Ther Med. 2016 Aug;12(2):901-908
39. T. J. Cawood. Smoking and Thyroid-Associated Ophthalmopathy: A Novel Explanation of the Biological Link . Volume 92, January 2007; 59–64
40. Bartalena L, Kahaly GJ, Baldeschi L et al. The 2021 European Group on Graves’
orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy. European Journal of Endocrinology (2021) 185, G43–G67
49
LAMPIRAN 2
DAFTAR RIWAYAT HIDUP
Nama : Muhammad Arief Munandar
NPM : 131221170010
TTL : Brebes, 01 November 1985
Alamat : Sapphire Residence Blok A NO.2 Kec. Talang, Kab. Tegal Nama Orang Tua : Ir. Kusnandar
Muzayanah S.pd Pendidikan Formal :
1. SD Negeri 2 Brebes (1992-1998) 2. SMP Negeri 2 Brebes (1998-2001) 3. SMA Negeri 1 Semarang (2001-2004)
4. Program Studi Sarjana Kedokteran, Fakultas Kedokteran Universitas Islam Sultan Agung Semarang (2004-2008)
5. Program Studi Profesi Dokter, Fakultas Kedokteran Universitas Islam Sultan Agung Semarang (2008-2010)
6. Program Pendidikan Dokter Spesialis I, Ilmu Kesehatan Mata, Fakultas Kedokteran Universitas Padjadjaran-Pusat Nasional Rumah Sakit Mata Cicendo, Bandung (2017-2022)
50
Pengalaman Kerja :
1. Dokter Puskesmas Kluwut, Brebes (2011-2012) 2. Dokter RSUD Brebes (2012-2014)
3. Dokter Puskesmas Wanasari, Brebes (2014-2017)
LAMPIRAN 3
PERHITUNGAN STATISTIK
Case Processing Summary Cases
Valid Missing Total
N Percent N Percent N Percent
Durasi 71 100.0% 0 0.0% 71 100.0%
Descriptives
Statistic Std. Error
Durasi
5% Trimmed Mean 11.3310
Median 6.0000
Variance 2554.940
Std. Deviation 50.54641
Minimum 1.00
Maximum 420.00
Range 419.00
Interquartile Range 9.00
Skewness 7.404 .285
Kurtosis 59.126 .563
Tests of Normality
Kolmogorov-Smirnova Shapiro-Wilk
Statistic df Sig. Statistic df Sig.
Durasi .368 71 .000 .277 71 .000
a. Lilliefors Significance Correction
52
Crosstabs
Case Processing Summary Cases
Valid Missing Total
N Percent N Percent N Percent
Usia * Kelompok 71 100.0% 0 0.0% 71 100.0%
Jenis Kelamin * Kelompok
71 100.0% 0 0.0% 71 100.0%
Status Tiroid * Kelompok 71 100.0% 0 0.0% 71 100.0%
Perokok * Kelompok 71 100.0% 0 0.0% 71 100.0%
TAO CAS * Kelompok 71 100.0% 0 0.0% 71 100.0%
TAO NOSPECS * Kelompok
71 100.0% 0 0.0% 71 100.0%
Usia * Kelompok Crosstabulation
Kelompok Total
All
Usia
10-20
Count 7 7
% within Kelompok 9.9% 9.9%
21-30
Count 9 9
% within Kelompok 12.7% 12.7%
31-40
Count 14 14
% within Kelompok 19.7% 19.7%
41-50
Count 18 18
% within Kelompok 25.4% 25.4%
51-60
Count 18 18
% within Kelompok 25.4% 25.4%
61-70
Count 5 5
% within Kelompok 7.0% 7.0%
Total
Count 71 71
% within Kelompok 100.0% 100.0%
Jenis Kelamin * Kelompok Crosstabulation
Kelompok Total
All
Jenis Kelamin
Laki-laki
Count 29 29
% within Kelompok 40.8% 40.8%
Perempuan
Count 42 42
% within Kelompok 59.2% 59.2%
Total
Count 71 71
% within Kelompok 100.0% 100.0%
Status Tiroid * Kelompok Crosstabulation
Kelompok Total
All
Status Tiroid
Hipotiroid
Count 6 6
% within Kelompok 8.5% 8.5%
Eutiroid Count 9 9
% within Kelompok 12.7% 12.7%
Hipertiroid
Count 56 56
% within Kelompok 78.9% 78.9%
Total
Count 71 71
% within Kelompok 100.0% 100.0%
Perokok * Kelompok Crosstabulation
Kelompok Total
All
Perokok
Ya
Count 27 27
% within Kelompok 38.0% 38.0%
Tidak Count 44 44
% within Kelompok 62.0% 62.0%
Total
Count 71 71
% within Kelompok 100.0% 100.0%
TAO CAS * Kelompok Crosstabulation
Kelompok Total
All
TAO CAS
Aktif
Count 36 36
% within Kelompok 50.7% 50.7%
Tidak Aktif Count 35 35
% within Kelompok 49.3% 49.3%
Total
Count 71 71
% within Kelompok 100.0% 100.0%
TAO NOSPECS * Kelompok Crosstabulation
Kelompok Total
All
TAO NOSPECS
Ringan
Count 13 13
% within Kelompok 18.3% 18.3%
Sedang
Count 39 39
% within Kelompok 54.9% 54.9%
Berat
Count 19 19
% within Kelompok 26.8% 26.8%
Total
Count 71 71
% within Kelompok 100.0% 100.0%
Case Processing Summary Cases
Valid Missing Total
N Percent N Percent N Percent
Grading NOSPECS 71 100.0% 0 0.0% 71 100.0%
Nilai CAS 71 100.0% 0 0.0% 71 100.0%
Descriptives
Statistic Std. Error
Grading NOSPECS
Mean 3.3380 .18270
95% Confidence Interval for Mean
Lower Bound 2.9737
Upper Bound 3.7024
5% Trimmed Mean 3.3599
Median 3.0000
Variance 2.370
Std. Deviation 1.53942
Minimum .00
Maximum 6.00
Range 6.00
Interquartile Range 3.00
Skewness -.375 .285
Kurtosis -.724 .563
Nilai CAS
Mean 2.4366 .21581
95% Confidence Interval for Mean
Lower Bound 2.0062
Upper Bound 2.8670
5% Trimmed Mean 2.3271
Median 3.0000
Variance 3.307
Std. Deviation 1.81842
Minimum .00
Maximum 7.00
Range 7.00
Interquartile Range 2.00
Skewness .626 .285
Kurtosis .077 .563
Tests of Normality
Kolmogorov-Smirnova Shapiro-Wilk
Statistic df Sig. Statistic df Sig.
Grading NOSPECS .160 71 .000 .924 71 .000
Nilai CAS .153 71 .000 .919 71 .000
a. Lilliefors Significance Correction
Nonparametric Correlations
Notes
Output Created 27-NOV-2021 20:31:52
Comments
Input
Data
D:\PROJECT\2021\11.
NOVEMBER\Dr Arief Mata\SPSS Dr Arief Mata
Active Dataset
DataSet1
Filter
<none>
Weight
<none>
Split File
<none>
N of Rows in Working Data File
71
Missing Value Handling
Definition of Missing User-defined missing values are treated as missing.
Cases Used
Statistics for each pair of variables are based on all the cases with valid data for that pair.
Syntax
NONPAR CORR
/VARIABLES=GradingNOSPECS NilaiCAS
/PRINT=SPEARMAN TWOTAIL NOSIG
/MISSING=PAIRWISE.
Resources
Processor Time 00:00:00.02
Elapsed Time 00:00:00.01
Number of Cases Allowed 174762 casesa a. Based on availability of workspace memory
Correlations
Grading NOSPECS
Nilai CAS
Spearman's rho
Grading NOSPECS
Correlation Coefficient 1.000 .668**
Sig. (2-tailed) . .000
N 71 71
Nilai CAS
Correlation Coefficient .668** 1.000
Sig. (2-tailed) .000 .
N 71 71
**. Correlation is significant at the 0.01 level (2-tailed).
Soft Tissue
Case Processing Summary
Soft Tissue Cases
Valid Missing Total
N Percent N Percent N Percent
Nilai CAS
Ya 53 100.0% 0 0.0% 53 100.0%
tidak 18 100.0% 0 0.0% 18 100.0%
Descriptives
Soft Tissue Statistic Std. Error
Nilai CAS Ya
Mean 3.0566 .22924
95% Confidence Interval for Mean
Lower Bound 2.5966
Upper Bound 3.5166
5% Trimmed Mean 3.0073
Median 3.0000
Variance 2.785
Std. Deviation 1.66889
Minimum .00
Maximum 7.00
Range 7.00
Interquartile Range 2.00
Skewness .500 .327
Kurtosis .447 .644
tidak
Mean .6111 .14323
95% Confidence Interval for Mean
Lower Bound .3089
Upper Bound .9133
5% Trimmed Mean .5679
Median 1.0000
Variance .369
Std. Deviation .60768
Minimum .00
Maximum 2.00
Range 2.00
Interquartile Range 1.00
Skewness .408 .536
Kurtosis -.513 1.038
Tests of Normality
Soft Tissue Kolmogorov-Smirnova Shapiro-Wilk
Statistic df Sig. Statistic df Sig.
Nilai CAS Ya .212 53 .000 .927 53 .003
tidak .294 18 .000 .752 18 .000
a. Lilliefors Significance Correction Nonparametric Tests
Proptosis
Case Processing Summary
Proptosis Cases
Valid Missing Total
N Percent N Percent N Percent
Nilai CAS
Ya 52 100.0% 0 0.0% 52 100.0%
tidak 19 100.0% 0 0.0% 19 100.0%
Descriptives
Proptosis Statistic Std. Error
Nilai CAS Ya
Mean 2.9038 .25357
95% Confidence Interval for Mean
Lower Bound 2.3948
Upper Bound 3.4129
5% Trimmed Mean 2.8376
Median 3.0000
Variance 3.344
Std. Deviation 1.82853
Minimum .00
Maximum 7.00
Range 7.00
Interquartile Range 2.00
Skewness .368 .330
Kurtosis -.012 .650
tidak
Mean 1.1579 .23275
95% Confidence Interval for Mean
Lower Bound .6689
Upper Bound 1.6469
5% Trimmed Mean 1.1199
Median 1.0000
Variance 1.029
Std. Deviation 1.01451
Minimum .00
Maximum 3.00
Range 3.00
Interquartile Range 2.00
Skewness .722 .524
Kurtosis -.310 1.014
Tests of Normality
Proptosis Kolmogorov-Smirnova Shapiro-Wilk
Statistic df Sig. Statistic df Sig.
Nilai CAS
Ya .171 52 .001 .935 52 .007
tidak .299 19 .000 .829 19 .003
a. Lilliefors Significance Correction
Nonparametric Tests
Extra ocular Muscle
Case Processing Summary Extra ocular
Muscle
Cases
Valid Missing Total
N Percent N Percent N Percent
Nilai CAS
Ya 34 100.0% 0 0.0% 34 100.0%
tidak 37 100.0% 0 0.0% 37 100.0%
Descriptives
Extra ocular Muscle Statistic Std. Error
Nilai CAS Ya
Mean 3.3529 .27648
95% Confidence Interval for Mean
Lower Bound 2.7904
Upper Bound 3.9154
5% Trimmed Mean 3.2810
Median 3.0000
Variance 2.599
Std. Deviation 1.61212
Minimum 1.00
Maximum 7.00
Range 6.00
Interquartile Range 2.00
Skewness .628 .403
Kurtosis .033 .788
tidak
Mean 1.5946 .26126
95% Confidence Interval for Mean
Lower Bound 1.0647
Upper Bound 2.1245
5% Trimmed Mean 1.4595
Median 1.0000
Variance 2.526
Std. Deviation 1.58919
Minimum .00
Maximum 7.00
Range 7.00
Interquartile Range 3.00
Skewness 1.200 .388
Kurtosis 2.024 .759
Tests of Normality Extra ocular
Muscle
Kolmogorov-Smirnova Shapiro-Wilk
Statistic df Sig. Statistic df Sig.
Nilai CAS
Ya .204 34 .001 .924 34 .021
tidak .240 37 .000 .841 37 .000
a. Lilliefors Significance Correction
Nonparametric Tests
Corneal
Case Processing Summary
Corneal Cases
Valid Missing Total
N Percent N Percent N Percent
Nilai CAS
Ya 19 100.0% 0 0.0% 19 100.0%
tidak 52 100.0% 0 0.0% 52 100.0%
Descriptives
Corneal Statistic Std. Error
Nilai CAS Ya
Mean 4.1579 .36884
95% Confidence Interval for Mean
Lower Bound 3.3830
Upper Bound 4.9328
5% Trimmed Mean 4.1754
Median 4.0000
Variance 2.585
Std. Deviation 1.60773
Minimum 1.00
Maximum 7.00
Range 6.00
Interquartile Range 2.00
Skewness .163 .524
Kurtosis -.261 1.014
tidak Mean 1.8077 .20187
95% Confidence Interval for Mean
Lower Bound 1.4024
Upper Bound 2.2130
5% Trimmed Mean 1.7222
Median 2.0000
Variance 2.119
Std. Deviation 1.45573
Minimum .00
Maximum 7.00
Range 7.00
Interquartile Range 2.00
Skewness .824 .330
Kurtosis 1.481 .650
Tests of Normality
Corneal Kolmogorov-Smirnova Shapiro-Wilk
Statistic df Sig. Statistic df Sig.
Nilai CAS Ya .171 19 .147 .952 19 .431
tidak .191 52 .000 .881 52 .000
a. Lilliefors Significance Correction Nonparametric Tests
Sight Lost (DON)
Case Processing Summary Sight Lost
(DON)
Cases
Valid Missing Total
N Percent N Percent N Percent
Nilai CAS
Ya 3 100.0% 0 0.0% 3 100.0%
tidak 68 100.0% 0 0.0% 68 100.0%
Descriptives
Sight Lost (DON) Statistic Std. Error
Nilai CAS Ya
Mean 5.3333 .88192
95% Confidence Interval for Mean
Lower Bound 1.5388
Upper Bound 9.1279
5% Trimmed Mean .
Median 5.0000
Variance 2.333
Std. Deviation 1.52753
Minimum 4.00
Maximum 7.00
Range 3.00
Interquartile Range .
Skewness .935 1.225
Kurtosis . .
tidak
Mean 2.3088 .20979
95% Confidence Interval for Mean
Lower Bound 1.8901
Upper Bound 2.7276
5% Trimmed Mean 2.1993
Median 2.0000
Variance 2.993
Std. Deviation 1.72996
Minimum .00
Maximum 7.00
Range 7.00
Interquartile Range 2.00
Skewness .645 .291
Kurtosis .257 .574
Tests of Normality
Sight Lost (DON)
Kolmogorov-Smirnova Shapiro-Wilk
Statistic df Sig. Statistic df Sig.
Nilai CAS
Ya .253 3 . .964 3 .637
tidak .158 68 .000 .916 68 .000
a. Lilliefors Significance Correction
Nonparametric Tests
Case Processing Summary Cases
Valid Missing Total
N Percent N Percent N Percent
Grading NOSPECS 53 100.0% 0 0.0% 53 100.0%
Nilai CAS 53 100.0% 0 0.0% 53 100.0%
Descriptives
Statistic Std. Error
Grading NOSPECS
Mean 3.9434 .15099
95% Confidence Interval for Mean
Lower Bound 3.6404
Upper Bound 4.2464
5% Trimmed Mean 3.9371
Median 4.0000
Variance 1.208
Std. Deviation 1.09921
Minimum 2.00
Maximum 6.00
Range 4.00
Interquartile Range 2.00
Skewness -.065 .327
Kurtosis -.863 .644
Nilai CAS
Mean 3.0566 .22924
95% Confidence Interval for Mean
Lower Bound 2.5966
Upper Bound 3.5166
5% Trimmed Mean 3.0073
Median 3.0000
Variance 2.785
Std. Deviation 1.66889
Minimum .00
Maximum 7.00
Range 7.00
Interquartile Range 2.00
Skewness .500 .327
Kurtosis .447 .644
Tests of Normality
Kolmogorov-Smirnova Shapiro-Wilk
Statistic df Sig. Statistic df Sig.
Grading NOSPECS .190 53 .000 .907 53 .001
Nilai CAS .212 53 .000 .927 53 .003
a. Lilliefors Significance Correction
Nonparametric Correlations
Correlations
Grading NOSPECS
Nilai CAS
Spearman's rho
Grading NOSPECS
Correlation Coefficient 1.000 .524**
Sig. (2-tailed) . .000
N 53 53
Nilai CAS
Correlation Coefficient .524** 1.000
Sig. (2-tailed) .000 .
N 53 53
**. Correlation is significant at the 0.01 level (2-tailed).
Case Processing Summary Cases
Valid Missing Total
N Percent N Percent N Percent
Grading NOSPECS 52 100.0% 0 0.0% 52 100.0%
Nilai CAS 52 100.0% 0 0.0% 52 100.0%
Descriptives
Statistic Std. Error
Grading NOSPECS
Mean 4.0769 .13126
95% Confidence Interval for Mean
Lower Bound 3.8134
Upper Bound 4.3404
5% Trimmed Mean 4.0299
Median 4.0000
Variance .896
Std. Deviation .94653
Minimum 3.00
Maximum 6.00
Range 3.00
Interquartile Range 2.00
Skewness .275 .330
Kurtosis -1.073 .650
Nilai CAS
Mean 2.9038 .25357
95% Confidence Interval for Mean
Lower Bound 2.3948
Upper Bound 3.4129
5% Trimmed Mean 2.8376
Median 3.0000
Variance 3.344
Std. Deviation 1.82853
Minimum .00
Maximum 7.00
Range 7.00
Interquartile Range 2.00
Skewness .368 .330
Kurtosis -.012 .650
Tests of Normality
Kolmogorov-Smirnova Shapiro-Wilk
Statistic df Sig. Statistic df Sig.
Grading NOSPECS .219 52 .000 .844 52 .000
Nilai CAS .171 52 .001 .935 52 .007
a. Lilliefors Significance Correction Nonparametric Correlations
Correlations
Grading NOSPECS
Nilai CAS
Spearman's rho
Grading NOSPECS
Correlation Coefficient 1.000 .539**
Sig. (2-tailed) . .000
N 52 52
Nilai CAS
Correlation Coefficient .539** 1.000
Sig. (2-tailed) .000 .
N 52 52
**. Correlation is significant at the 0.01 level (2-tailed).
Case Processing Summary Cases
Valid Missing Total
N Percent N Percent N Percent
Grading NOSPECS 34 100.0% 0 0.0% 34 100.0%
Nilai CAS 34 100.0% 0 0.0% 34 100.0%
Descriptives
Statistic Std. Error
Grading NOSPECS
Mean 4.5882 .10443
95% Confidence Interval for Mean
Lower Bound 4.3758
Upper Bound 4.8007
5% Trimmed Mean 4.5425
Median 5.0000
Variance .371
Std. Deviation .60891
Minimum 4.00
Maximum 6.00
Range 2.00
Interquartile Range 1.00
Skewness .497 .403
Kurtosis -.564 .788
Nilai CAS
Mean 3.3529 .27648
95% Confidence Interval for Mean
Lower Bound 2.7904
Upper Bound 3.9154
5% Trimmed Mean 3.2810
Median 3.0000
Variance 2.599
Std. Deviation 1.61212
Minimum 1.00
Maximum 7.00
Range 6.00
Interquartile Range 2.00
Skewness .628 .403
Kurtosis .033 .788
Tests of Normality
Kolmogorov-Smirnova Shapiro-Wilk
Statistic df Sig. Statistic df Sig.
Grading NOSPECS .304 34 .000 .743 34 .000
Nilai CAS .204 34 .001 .924 34 .021
a. Lilliefors Significance Correction Nonparametric Correlations
Correlations
Grading NOSPECS
Nilai CAS
Spearman's rho
Grading NOSPECS
Correlation Coefficient 1.000 .593**
Sig. (2-tailed) . .000
N 34 34
Nilai CAS
Correlation Coefficient .593** 1.000
Sig. (2-tailed) .000 .
N 34 34
**. Correlation is significant at the 0.01 level (2-tailed).
Case Processing Summary Cases
Valid Missing Total
N Percent N Percent N Percent
Grading NOSPECS 19 100.0% 0 0.0% 19 100.0%
Nilai CAS 19 100.0% 0 0.0% 19 100.0%
Descriptives
Statistic Std. Error
Grading NOSPECS
Mean 5.1579 .08595
95% Confidence Interval for Mean
Lower Bound 4.9773
Upper Bound 5.3385
5% Trimmed Mean 5.1199
Median 5.0000
Variance .140
Std. Deviation .37463
Minimum 5.00
Maximum 6.00
Range 1.00
Interquartile Range .00
Skewness 2.041 .524
Kurtosis 2.410 1.014
Nilai CAS
Mean 4.1579 .36884
95% Confidence Interval for Mean
Lower Bound 3.3830
Upper Bound 4.9328
5% Trimmed Mean 4.1754
Median 4.0000
Variance 2.585
Std. Deviation 1.60773
Minimum 1.00
Maximum 7.00
Range 6.00
Interquartile Range 2.00
Skewness .163 .524
Kurtosis -.261 1.014
Tests of Normality
Kolmogorov-Smirnova Shapiro-Wilk
Statistic df Sig. Statistic df Sig.
Grading NOSPECS .505 19 .000 .445 19 .000
Nilai CAS .171 19 .147 .952 19 .431
a. Lilliefors Significance Correction Nonparametric Correlations
Correlations
Grading NOSPECS
Nilai CAS
Spearman's rho
Grading NOSPECS
Correlation Coefficient 1.000 .336
Sig. (2-tailed) . .159
N 19 19
Nilai CAS
Correlation Coefficient .336 1.000
Sig. (2-tailed) .159 .
N 19 19
Case Processing Summary Cases
Valid Missing Total
N Percent N Percent N Percent
Grading NOSPECS 3 100.0% 0 0.0% 3 100.0%
Nilai CAS 3 100.0% 0 0.0% 3 100.0%
Descriptivesa
Statistic Std. Error
Nilai CAS
Mean 5.3333 .88192
95% Confidence Interval for Mean
Lower Bound 1.5388
Upper Bound 9.1279
5% Trimmed Mean .
Median 5.0000
Variance 2.333
Std. Deviation 1.52753
Minimum 4.00
Maximum 7.00
Range 3.00
Interquartile Range .
Skewness .935 1.225
Kurtosis . .
a. Grading NOSPECS is constant. It has been omitted.
Tests of Normalitya
Kolmogorov-Smirnovb Shapiro-Wilk
Statistic df Sig. Statistic df Sig.
Nilai CAS .253 3 . .964 3 .637
a. Grading NOSPECS is constant. It has been omitted.
b. Lilliefors Significance Correction Correlations
Correlations
Grading NOSPECS Nilai CAS
Grading NOSPECS
Pearson Correlation .a .a
Sig. (2-tailed) .
N 3 3
Nilai CAS
Pearson Correlation .a 1
Sig. (2-tailed) .
N 3 3
a. Cannot be computed because at least one of the variables is constant.
Nonparametric Correlations
Correlations Nilai CAS
Durasi Onset Status Tiroid
Spearman's rho
Nilai CAS
Correlation Coefficient
1.000 .100 -.078 -.142
Sig. (2-tailed) . .405 .515 .236
N 71 71 71 71
Durasi
Correlation Coefficient
.100 1.000 .580** -.117
Sig. (2-tailed) .405 . .000 .332
N 71 71 71 71
Onset
Correlation Coefficient
-.078 .580** 1.000 -.101
Sig. (2-tailed) .515 .000 . .401
N 71 71 71 71
Status Tiroid
Correlation Coefficient
-.142 -.117 -.101 1.000
Sig. (2-tailed) .236 .332 .401 .
N 71 71 71 71
**. Correlation is significant at the 0.01 level (2-tailed).
Perokok
Case Processing Summary
Perokok Cases
Valid Missing Total
N Percent N Percent N Percent
Nilai CAS Ya 27 100.0% 0 0.0% 27 100.0%
Tidak 44 100.0% 0 0.0% 44 100.0%
Descriptives
Perokok Statistic Std. Error
Nilai CAS Ya
Mean 3.3333 .36201
95% Confidence Interval for Mean
Lower Bound 2.5892
Upper Bound 4.0775
5% Trimmed Mean 3.3004
Median 3.0000
Variance 3.538
Std. Deviation 1.88108
Minimum .00
Maximum 7.00
Range 7.00
Interquartile Range 3.00
Skewness .337 .448
Kurtosis -.511 .872
Tidak
Mean 1.8864 .23494
95% Confidence Interval for Mean
Lower Bound 1.4126
Upper Bound 2.3602
5% Trimmed Mean 1.7980
Median 2.0000
Variance 2.429
Std. Deviation 1.55841
Minimum .00
Maximum 7.00
Range 7.00
Interquartile Range 2.00
Skewness .738 .357
Kurtosis .936 .702
Tests of Normality
Perokok Kolmogorov-Smirnova Shapiro-Wilk
Statistic df Sig. Statistic df Sig.
Nilai CAS
Ya .163 27 .064 .954 27 .267
Tidak .193 44 .000 .883 44 .000
a. Lilliefors Significance Correction
Nonparametric Tests
Crosstabs
Case Processing Summary Cases
Valid Missing Total
N Percent N Percent N Percent
TAO NOSPECS * TAO CAS
71 100.0% 0 0.0% 71 100.0%
TAO NOSPECS * TAO CAS Crosstabulation
TAO CAS Total
Aktif Tidak Aktif
TAO NOSPECS
Ringan
Count 0 13 13
Expected Count 6.6 6.4 13.0
% within TAO CAS 0.0% 37.1% 18.3%
Sedang
Count 19 20 39
Expected Count 19.8 19.2 39.0
% within TAO CAS 52.8% 57.1% 54.9%
Berat
Count 17 2 19
Expected Count 9.6 9.4 19.0
% within TAO CAS 47.2% 5.7% 26.8%
Total
Count 36 35 71
Expected Count 36.0 35.0 71.0
% within TAO CAS 100.0% 100.0% 100.0%
Chi-Square Tests
Value df Asymp. Sig. (2-
sided)
Pearson Chi-Square 24.859a 2 .000
Likelihood Ratio 31.586 2 .000
Linear-by-Linear Association 24.401 1 .000
N of Valid Cases 71
a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 6.41.
Crosstabs
Case Processing Summary Cases
Valid Missing Total
N Percent N Percent N Percent
Kategori Durasi TAO * Kelompok
71 97.3% 2 2.7% 73 100.0%
Kategori Durasi TAO * Kelompok Crosstabulation
Kelompok Total All
Kategori Durasi TAO
Durasi TAO >24
Count 11 11
% within Kelompok 15.5% 15.5%
Durasi TAO <=24
Count 60 60
% within Kelompok 84.5% 84.5%
Total
Count 71 71
% within Kelompok 100.0% 100.0%
nomerusiaJenis kelaminDurasi (bulan)
Status tiroidStatus perokokCASDerajat NOSP 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
70 26 45 51 23 62 20 40 58 70 51 40 41 51 41 43 42 55 44 47 Wanita Wanita Laki-laki Wanita Laki-laki Laki-laki Wanita Laki-laki Laki-laki Wanita Wanita Laki-laki Wanita Wanita Laki-laki Laki-laki Laki-laki Wanita Wanita Wanita
48 10 9 48 3 60 5 3 2 24 12 12 1 24 6 5 2 48 2 1
Hipertiroid Hipertiroid Hipertiroid Hipertiroid Hipertiroid Hipotiroid Hipertiroid Hipertiroid Hipertiroid Hipotiroid Hipertiroid Hipertiroid Hipertiroid Hipertiroid Hipertiroid Hipertiroid Hipertiroid Eutiroid Eutiroid Hipertiroid Tidak Tidak Perokok Tidak Perokok Perokok Tidak Perokok Perokok Tidak Tidak Tidak Tidak Tidak Perokok Perokok Perokok Tidak Tidak Tidak
2 3 5 2 4 2 3 1 3 3 4 3 1 4 2 1 2 1 3 3
4 5 6 4 5 4 3 1 3 2 5 4 1 6 5 1 1 3 3 3
21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 18 20 31 50 59 18 26 37 52 54 22 62 33 52 18 35 33 54 47 60 37 47 Wanita Wanita Wanita Wanita Laki-laki Laki-laki Wanita Wanita Wanita Wanita Laki-laki Wanita Wanita Wanita Wanita Wanita Wanita Laki-laki Wanita Laki-laki Laki-laki Laki-laki
12 24 6 24 7 1 6 12 9 6 3 12 2 6 18 5 5 3 5 48 3 3
Hipertiroid Eutiroid Eutiroid Hipertiroid Hipertiroid Hipertiroid Hipertiroid Hipotiroid Hipertiroid Hipertiroid Hipertiroid Hipertiroid Hipertiroid Hipertiroid Hipertiroid Hipertiroid Hipertiroid Hipertiroid Hipertiroid Hipertiroid Hipertiroid Hipertiroid Tidak Tidak Tidak Tidak Perokok Tidak Tidak Tidak Tidak Perokok Perokok Perokok Tidak perokok Tidak Perokok Tidak Perokok Perokok Perokok Perokok Perokok
3 3 1 4 6 0 1 7 3 1 3 3 1 3 1 3 0 4 4 2 0 3
3 3 2 5 5 1 2 3 4 1 5 4 0 2 1 5 1 4 3 4 1 4
43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 57 55 35 42 27 42 57 20 26 44 33 37 56 51 20 61 30 39 47 33 21 35 Laki-laki Wanita Laki-laki Wanita Wanita Laki-laki Wanita Wanita Wanita Wanita Laki-laki Laki-laki Laki-laki Wanita Wanita Wanita Laki-laki Laki-laki Laki-laki Laki-laki Wanita Wanita
1 4 12 6 36 4 48 3 2 3 18 8 1 4 2 35 34 1 2 12 2 12
Hipertiroid Hipertiroid Hipertiroid Hipertiroid Hipertiroid Hipertiroid Hipertiroid Hipertiroid Hipertiroid Hipertiroid Hipertiroid Eutiroid Hipotiroid Hipertiroid Eutiroid Hipotiroid Eutiroid Hipotiroid Hipertiroid Hipertiroid Hipertiroid Hipertiroid Tidak Perokok Perokok Tidak Tidak Tidak Tidak Tidak Tidak Tidak Perokok Perokok Perokok Tidak Perokok Tidak Tidak Tidak Tidak Tidak Tidak Tidak
2 6 4 0 1 2 0 3 0 3 7 3 5 0 7 1 1 1 1 0 0 3
2 5 4 3 3 4 3 3 1 4 6 5 5 3 5 4 4 4 5 3 3 4